亚辉龙2025年上半年研发投入1.43亿元 化学发光业务竞争力再增强

Core Insights - Shenzhen Yahui Long Biotechnology Co., Ltd. reported its 2025 semi-annual performance, achieving operating revenue of 808 million yuan and a net profit attributable to shareholders of 26.27 million yuan [1] - The company has made significant advancements in research and development, with an investment of 143 million yuan and the approval of 14 new domestic registration certificates for chemiluminescent detection reagents [1] - The company has expanded its overseas market presence, installing 544 chemiluminescent instruments, with a notable increase in reagent sales revenue by 60.82% year-on-year [1] Financial Performance - Operating revenue for the first half of 2025 reached 808 million yuan [1] - Net profit attributable to shareholders was 26.27 million yuan, while the net profit excluding non-recurring items was 50.03 million yuan [1] - Total assets amounted to 4.299 billion yuan, and net assets were 2.668 billion yuan [1] Research and Development - The company invested 143 million yuan in R&D during the first half of 2025 [1] - A total of 14 new chemiluminescent detection reagent registration certificates were approved, enhancing the product lineup [1] - The company has 184 chemiluminescent diagnostic projects with domestic and international registration certificates, including 62 projects in autoimmune diagnostics [1] Market Expansion - The company installed 544 chemiluminescent instruments, including 47 units of the 300-speed model [1] - The overseas business covers 120 countries and regions across the Americas, Europe, Asia, and Africa [1] - Reagent sales revenue increased by 60.82% year-on-year, indicating strong market demand [1] Smart Manufacturing - The company has advanced its "smart manufacturing" initiatives, completing the smart upgrade of two production lines for reagent manufacturing [2] - The MES system is being steadily implemented, enhancing the digitalization level of production lines and improving production efficiency [2]